Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
28.21
-0.27 (-0.95%)
At close: Apr 10, 2026, 4:00 PM EDT
28.24
+0.03 (0.11%)
After-hours: Apr 10, 2026, 7:32 PM EDT
Roivant Sciences Employees
Roivant Sciences had 750 employees as of March 31, 2025. The number of employees decreased by 158 or -17.40% compared to the previous year.
Employees
750
Change (1Y)
-158
Growth (1Y)
-17.40%
Revenue / Employee
$17,747
Profits / Employee
-$1,078,987
Market Cap
20.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Jazz Pharmaceuticals | 2,890 |
| Incyte | 2,844 |
| Ionis Pharmaceuticals | 1,402 |
| Ascendis Pharma | 1,189 |
| Revolution Medicines | 883 |
ROIV News
- 8 days ago - Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED) - GlobeNewsWire
- 8 days ago - Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) - GlobeNewsWire
- 13 days ago - New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis - GlobeNewsWire
- 5 weeks ago - Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute - Reuters
- 5 weeks ago - Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 5 weeks ago - Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewsWire
- 5 weeks ago - Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis - GlobeNewsWire
- 2 months ago - Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire